Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis

被引:27
|
作者
Inchingolo, Riccardo [1 ]
Varone, Francesco [1 ]
Sgalla, Giacomo [1 ]
Richeldi, Luca [1 ]
机构
[1] Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc & Thorac Sci, Pulm Med Unit, Largo Gemelli 8, I-00168 Rome, Italy
关键词
Idiopathic pulmonary fibrosis; biomarkers; personalized medicine; extracellular matrix remodeling and fibroproliferation; alveolar epithelial cell dysfunction; immune dysfunction; MUC5B PROMOTER POLYMORPHISM; SURFACTANT-PROTEIN-A; REGULATORY T-CELLS; CIRCULATING FIBROCYTES; TELOMERE LENGTH; LYSYL OXIDASE; ACUTE EXACERBATION; MATRIX METALLOPROTEINASE-7; INTERSTITIAL PNEUMONIA; PLASMA-CONCENTRATIONS;
D O I
10.1080/17476348.2019.1553620
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to respiratory failure, and ultimately to death. It is characterized by marked heterogeneity regarding its clinical course. Despite significant progress in the understanding of its pathogenesis, the course of the disease and the response to treatment of an individual patient cannot be reliably predicted today. Areas covered: Non-invasive biomarkers, in particular serum biomarkers, for the (early) diagnosis, differential diagnosis, prognosis, and prediction of therapeutic response are described. The molecules are classified according to their involvement into alveolar epithelial cell injury, fibroproliferation, and matrix remodeling as well as immune regulation. Furthermore, genetic variants of TOLLIP, MUC-5B, and other genes associated with a differential response to treatment and with the development and/or the prognosis of IPF are reported. Expert commentary: The combination of multiple biomarkers may identify comprehensive biomarker signatures in IPF patients. This is a way to apply personalized medicine approach to patient affected by IPF in order to not only improve our ability to diagnose and treat disease but also offer the potential to detect disease at an earlier stage, when it is potentially easier to treat effectively.
引用
收藏
页码:39 / 51
页数:13
相关论文
共 50 条
  • [1] Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
    Zhu, Weiwei
    Liu, Chunquan
    Tan, Chunting
    Zhang, Jie
    HELIYON, 2024, 10 (01)
  • [2] Existing and emerging treatments for idiopathic pulmonary fibrosis
    Kolilekas, Lykourgos
    Papiris, Spyridon
    Bouros, Demosthenes
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (03) : 229 - 239
  • [3] Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies
    Magnini, Daniele
    Montemurro, Giuliano
    Iovene, Bruno
    Tagliaboschi, Linda
    Gerardi, Rafael Emanuele
    Lo Greco, Erminia
    Bruni, Teresa
    Fabbrizzi, Alessio
    Lombardi, Francesco
    Richeldi, Luca
    RESPIRATION, 2017, 93 (06) : 379 - 395
  • [4] PREDICTION OF DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS
    WELLS, AU
    DUBOIS, RM
    EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (04) : 637 - 639
  • [5] Vimentin serum biomarkers are differentially related to disease progression in idiopathic pulmonary fibrosis (IPF)
    Simoes, Filipa B.
    Hoyer, Nils
    Prior, Thomas S.
    Jessen, Henrik
    Fredriksen, Peder
    Karsdal, Morten
    Leeming, Diana J.
    Bendstrup, Elisabeth
    Sand, Jannie M. B.
    Shaker, Saher B.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [6] Prognostic Value of Serum Biomarkers in Patients with Idiopathic Pulmonary Fibrosis in Relation to Disease Progression
    Domvri, Kalliopi
    Organtzis, Ioannis
    Apostolopoulos, Apostolos
    Fouka, Evangelia
    Kontakiotis, Theodoros
    Papakosta, Despoina
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [7] Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis
    Cavalli, Francesco
    Puxeddu, Ermanno
    Teodori, Elisa
    Sforza, Maurizia
    De Marco, Patrizia
    Rogliani, Paola
    MINERVA RESPIRATORY MEDICINE, 2021, 60 (03): : 73 - 86
  • [8] MOLECULAR BIOMARKERS IN IDIOPATHIC PULMONARY FIBROSIS AND DISEASE SEVERITY
    Crestani, B.
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2013, 30 : 27 - 32
  • [9] Changes in Biomarkers of Collagen Synthesis and Degradation Correlate with Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis
    Organ, L.
    Saini, G.
    Molyneaux, P. L.
    Braybrooke, R.
    Marshall, R.
    Fahy, W.
    Duggan, A.
    Kang'ombe, A.
    Simpson, J.
    Karsdal, M.
    Leeming, D. J.
    Jenkins, R. G.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] The Proteome Signature Of Disease Progression In Idiopathic Pulmonary Fibrosis
    O'Dwyer, D. N.
    Ashley, S.
    Xia, M.
    Murray, S.
    Grant, E.
    White, E. S.
    Flaherty, K. R.
    Martinez, F. J.
    Moore, B. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193